Abstract CT153: Pemigatinib in Chinese Patients with Advanced/metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Fusion or Rearrangement: Updated Overall Survival from an Open-Label, Single-Arm, Multicenter Phase II Study
Cancer Research（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined